Psoriatic Disease News

Sotyktu significantly outperformed placebo for the treatment of psoriatic arthritis in a phase 3 trial, meeting key endpoints at 16 weeks, according to late-breaking data presented at the American Academy of Dermatology annual meeting.

ORLANDO — Interleukin-23 inhibitors may be able to reduce the risk of developing psoriatic arthritis among patients with psoriasis, according to a speaker at the American Academy of Dermatology Annual Meeting.

ORLANDO — The American Academy of Dermatology annual meeting was packed with “massive advancements” across the field, Joel M. Gelfand, MD, MSCE, chief medical editor of Healio Dermatology, said.

ORLANDO — Outgoing American Academy of Dermatology President Seemal R. Desai, MD, FAAD, passed the torch to Susan C. Taylor, MD, FAAD, who said she will continue pushing efforts to unify the organization during “a time of great disruption.”

ORLANDO — A once-daily, oral tyrosine kinase 2 inhibitor was safe and “highly effective” in adults with moderate to severe plaque psoriasis, according to a presenter at the American Academy of Dermatology Annual Meeting.

Four biosimilars for Stelara have launched in the United States this year following legal settlements with the reference product manufacturer, Janssen Pharmaceuticals, which set timelines for their market entries.

In honor of American Heart Month, Healio Dermatology interviewed experts and explored the connection between skin disease and heart health.

Beneath the Surface is a video series in which Joel M. Gelfand, MD, MSCE, Healio Dermatology Chief Medical Editor, discusses hot topics in the field with leading experts.

In this Healio exclusive video, Lawrence F. Eichenfield, MD, talks about takeaways in updates on topical treatments for pediatric and adolescent psoriasis discussed at Maui Derm 2025.